Generic Vimovo Availability

Vimovo is a brand name of esomeprazole/naproxen, approved by the FDA in the following formulation(s):

VIMOVO (esomeprazole magnesium; naproxen - tablet, delayed release;oral)

  • Manufacturer: HORIZON PHARMA
    Approval date: April 30, 2010
    Strength(s): EQ 20MG BASE;375MG [AB], EQ 20MG BASE;500MG [RLD] [AB]

Has a generic version of Vimovo been approved?

A generic version of Vimovo has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Vimovo and have been approved by the FDA:

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM (esomeprazole magnesium; naproxen tablet, delayed release;oral)

  • Manufacturer: DR REDDYS LABS LTD
    Approval date: September 27, 2013
    Strength(s): EQ 20MG BASE;375MG [AB], EQ 20MG BASE;500MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vimovo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compositions
    Patent 5,714,504
    Issued: February 3, 1998
    Inventor(s): Lindberg; Per Lennart & Von Unge; Sverker
    Assignee(s): Astra Aktiebolag
    The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H- benzimidazole or (-)-5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
    Patent expiration dates:
    • February 3, 2015
      ✓ 
      Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
      ✓ 
      Drug product
    • August 3, 2015
      ✓ 
      Pediatric exclusivity
  • Omeprazole magnesium salt form
    Patent 5,900,424
    Issued: May 4, 1999
    Inventor(s): Kallstrom; Lars .ANG.ke & Nygren; Monica Annelie
    Assignee(s): Astra Aktiebolag
    A novel compound form of magnesium omeprazole useful in the manufacture of pharmaceutical formulations, the use of the product and the process for its production are described.
    Patent expiration dates:
    • May 4, 2016
      ✓ 
      Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
      ✓ 
      Drug substance
    • November 4, 2016
      ✓ 
      Pediatric exclusivity
  • Form of S-omeprazole
    Patent 6,369,085
    Issued: April 9, 2002
    Inventor(s): Hanna; Cotton & Anders; Kronström & Anders; Mattson & Eva; Möller
    Assignee(s): AstraZeneca AB
    The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Patent expiration dates:
    • May 25, 2018
      ✓ 
      Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 25, 2018
      ✓ 
      Pediatric exclusivity
  • Compounds
    Patent 6,875,872
    Issued: April 5, 2005
    Inventor(s): Lindberg; Per Lennart & Von Unge; Sverker
    Assignee(s): AstraZeneca
    The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
    Patent expiration dates:
    • May 27, 2014
      ✓ 
      Drug substance
    • November 27, 2014
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical compositions for the coordinated delivery of NSAIDs
    Patent 6,926,907
    Issued: August 9, 2005
    Inventor(s): Plachetka; John R.
    Assignee(s): Pozen Inc.
    The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Patent expiration dates:
    • February 28, 2023
      ✓ 
      Patent use: RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
      ✓ 
      Drug product
  • Form of S-omeprazole
    Patent 7,411,070
    Issued: August 12, 2008
    Inventor(s): Cotton; Hanna & Kronström; Anders & Mattson; Anders & Möller; Eva
    Assignee(s): AstraZeneca AB
    The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Patent expiration dates:
    • May 25, 2018
      ✓ 
      Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
      ✓ 
      Drug substance
    • November 25, 2018
      ✓ 
      Pediatric exclusivity
  • Form of S-omeprazole
    Patent 7,745,466
    Issued: June 29, 2010
    Inventor(s): Cotton; Hanna & Kronström; Anders & Mattson; Anders & Möller; Eva
    Assignee(s): AstraZeneca AB
    The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Patent expiration dates:
    • October 13, 2018
      ✓ 
      Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
      ✓ 
      Drug product
  • Pharmaceutical compositions for the coordinated delivery of NSAIDs
    Patent 8,557,285
    Issued: October 15, 2013
    Assignee(s): Pozen Inc.
    The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Patent expiration dates:
    • May 31, 2022
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Suffering from knee pain? Find out how real people manage OA of the Knee. Watch Video

Close
Hide
(web2)